Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
3 Visningar
administrator
07/30/23
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
Visa mer
Facebook-kommentarer
Inga kommentarer hittades